Clinical Trial Update: A 90 Day Observational Study as an Extension to the Phase 3,Open Labeled Exploratory Study of RELiZORB

View source ↗

Summary

A 90-day observational extension study of RELiZORB for short bowel syndrome with malabsorption is being conducted as an extension to a Phase 3 open-label study,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malabsorption
• Short Bowel Syndrome

Drugs mentioned

• RELiZORB

Snippet

Sponsor: Boston Children's Hospital | Conditions: Short Bowel Syndrome, Malabsorption | Status: ENROLLING_BY_INVITATION